Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110 participants
OBSERVATIONAL
2009-07-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stratus Versus Cirrus OCT in AMD
NCT00568191
Reproducibility of Cirrus Optical Coherence Tomography Measurements
NCT00643422
Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.
NCT00731458
Imaging of the Angiofibrotic Switch in Neovascular AMD
NCT03838679
Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies
NCT00408720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
Cirrus-Spectralis
512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
group 2
intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
Cirrus-Spectralis
512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
group 3
intervention 2 sequence of observers: 1,2,1,2
Spectralis-Cirrus
retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
group 4
intervention 2 sequence of observers: 2,1,2,1
Spectralis-Cirrus
retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
group 5
intervention 1 sequence of observers 1,1,2,2
Cirrus-Spectralis
512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
group 6
intervention 1 sequence of observers 2,2,1,1
Cirrus-Spectralis
512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
group 7
intervention 2 sequence of observers: 1,1,2,2
Spectralis-Cirrus
retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
group 8
intervention 2 sequence of observers: 2,2,1,1
Spectralis-Cirrus
retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cirrus-Spectralis
512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
Spectralis-Cirrus
retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Visualization of the macula not possible (dens cataract, vitreous haemorrhage)
* Not consented patients
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Binder, MD, Prof
Role: STUDY_CHAIR
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Krebs I, Smretschnig E, Moussa S, Brannath W, Womastek I, Binder S. Quality and reproducibility of retinal thickness measurements in two spectral-domain optical coherence tomography machines. Invest Ophthalmol Vis Sci. 2011 Sep 1;52(9):6925-33. doi: 10.1167/iovs.10-6612.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-086-0609
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.